IMMUNOVANT, INC. Retained Earnings
IMMUNOVANT, INC. (IMVT) had Retained Earnings of -$1.90 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.90B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.75B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.60B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.49B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$1.90B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$1.75B 10-Q · filed 2026-08-06 | |
| 2025-12-31 | -$1.60B 10-Q · filed 2026-02-06 | |
| 2025-09-30 | -$1.49B 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$1.36B 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$1.24B 10-K · filed 2026-05-20 | |
| 2024-12-31 | -$1.13B 10-Q · filed 2025-02-06 | |
| 2024-09-30 | -$1.02B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$912.83M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$825.68M 10-K · filed 2025-05-29 | |
| 2023-12-31 | -$750.36M 10-Q · filed 2024-02-12 | |
| 2023-09-30 | -$698.95M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$640.28M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$566.35M 10-K · filed 2024-05-29 | |
| 2022-12-31 | -$506.92M 10-Q · filed 2023-02-03 | |
| 2022-09-30 | -$443.69M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | -$395.76M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | -$355.39M 10-K · filed 2023-05-22 | |
| 2021-12-31 | -$308.22M 10-Q · filed 2022-02-04 | |
| 2021-09-30 | -$266.83M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | -$229.13M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$198.66M 10-K · filed 2022-06-08 | |
| 2020-12-31 | -$170.50M 10-Q · filed 2021-02-16 | |
| 2020-09-30 | -$138.72M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | -$117.93M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | -$91.23M 10-K · filed 2021-06-01 | |
| 2019-12-31 | -$70.67M 10-Q · filed 2020-02-14 | |
| 2019-09-30 | $306.94K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $181.85K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | -$24.84M 10-K · filed 2020-06-29 | -$898.00 10-Q · filed 2019-06-12 |
| 2018-12-31 | -$448.00 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |